Validation of the Neuropathy Impairment Score (NIS) for use in Russian-speaking patients with chronic inflammatory demyelinating polyneuropathy

Background. A clinical application of scales and questionnaires is essential for the objective evaluation of treatment response, disease course, quality of life and the disability level in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Neuropathy Impairment Score (NIS) has become widespread in epidemiological and clinical studies of various polyneuropathies, including CIDP. However, its application in Russia is limited by the absence of its validated version for Russian-speaking patients. Aim. To develop the Russian validated version of the NIS for its application in patients with CIDP. Materials and methods. The study involved 50 patients with CIDP (25 with multifocal variant of CIDP (Lewis–Sumner syndrome) and 25 with typical CIDP). The validation process included two stages: translation and linguocultural ratification of the scale according to the standard protocol and an assessment of its psychometric properties, such as reliability, validity and sensitivity. Results. The developed Russian version of the NIS demonstrated the high level of reliability, sensitivity and validity. Conclusion. The validated Russian version of the NIS can be recommended for application in research and clinical practice.

1. Broers M.C., Bunschoten C., Nieboer D. et al. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review and meta-analysis. Neuroepidemiology 2019;52(3–4):161–72. DOI: 10.1159/000494291

2. Kieseier B.C., Mathey E.K., Sommer C. et al. Immune-mediated neuropathies. Nat Rev Dis Primers 2018;4(1):31. DOI: 10.1038/s41572-018-0027-2

3. Van den Bergh P.Y.K., van Doorn P.A., Hadden R.D.M. et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst 2021;26(3):242–68. DOI: 10.1111/jns.12455

4. Oaklander A.L., Lunn M.P., Hughes R.A. et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): An overview of systematic reviews. Cochrane Database Syst Rev 2017;13;1(1):CD010369. DOI: 10.1002/14651858.CD010369.pub2

5. Stino A.M., Naddaf E., Dyck P.J. et al. Chronic inflammatory demyelinating polyradiculoneuropathy – Diagnostic pitfalls and treatment approach. Muscle Nerve 2021;63(2):157–69. DOI: 10.1002/mus.27046

6. Fisse A.L., Motte J., Grüter T. et al. Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy. Neurol Res Pract 2020;2:42. DOI: 10.1186/s42466-020-00088-8

7. Arestova А. S., Melnik Е. А., Zaytsev A. B. et al. Inflammatory Neuropathy Cause and Treatment (INCAT) Scale for the assessment of disability level in patients with chronic inflammatory demyelinating polyneuropathy: linguocultural ratification in Russia. Nervno-myshechnye bolezni = Neuromuscular Diseases 2021;11(4):26–33. (In Russ.). DOI: 10.17650/2222-8721-2021-11-4-26-33

8. Suponeva N.A., Arestova А.S., Melnik Е.А. et al. Validation of the Medical Research Council sum score (MRCss) for use in Russian-speaking patients with chronic inflammatory demyelinating polyneuropathy. Nervno-myshechnye bolezni = Neuromuscular Diseases 2023;13(1):68–74. (In Russ.). DOI: 10.17650/2222-8721-2023-13-1-68-74

9. Van Nes S.I., Vanhoutte E.K., van Doorn P.A. et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 2011;76(4):337–45. DOI: 10.1212/WNL.0b013e318208824b

10. Dyck P.J., Sherman W.R., Hallcher L.M. et al. Human diabetic endoneurial sorbitol, fructose, and myo-inosirol related to sural nerve morphomerry. Ann Neurol 1980;8:590–6.

11. Dyck P.J., Boes C.J., Mulder D. et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst 2005;10(2):158–73. DOI: 10.1111/j.1085-9489.2005.0010206.x

12. Dyck P.J., Litchy W.J., Kratz K.M. et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838–45.

13. Dyck P.J., Daube J., OʼBrien P. et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461–5.

14. Dyck P.J., Taylor B.V., Davies J.L. et al. Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Muscle Nerve 2015;52(4):488–97. DOI: 10.1002/mus.24707

15. Benson M.D., Waddington-Cruz M., Berk J.L. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018;5;379(1):22–31. DOI: 10.1056/NEJMoa1716793

16. Dyck P.J.B., González-Duarte A., Obici L. et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7. J Neurol Sci 2019;15(405):116424. DOI: 10.1016/j.jns.2019.116424

17. Hsieh R.Y., Huang I.C., Chen C. et al. Effects of oral alpha-lipoic acid treatment on diabetic polyneuropathy: A meta-analysis and systematic review. Nutrients 2023;18;15(16):3634. DOI: 10.3390/nu15163634

18. Baicus C., Purcarea A., von Elm E. et al. Alpha-lipoic acid for diabetic peripheral neuropathy. Cochrane Database Syst Rev 2024;11;1(1):CD012967. DOI: 10.1002/14651858

19. Mokkink L.B., Prinsen C.A., Bouter L.M et al. The Consensusbased Standards for the Selection of Health Measurement Instruments (COSMIN) and how to select an outcome measurement instrument. Braz J Phys Ther 2016;19;20(2):105–13. DOI: 10.1590/bjpt-rbf.2014.0143

20. Beaton D., Bombardier C., Guillemin F. et al. Recommendations for the cross-cultural adaptation of health status measures. New York: American Academy of Orthopaedic Surgeons, 2002. Pp. 1–9.

21. Serdar C.C., Cihan M., Yücel D. et al. Sample size, power and effect size revisited: Simplified and practical approaches in pre-clinical, clinical and laboratory studies. Biochem Med (Zagreb) 2021;31:010502. DOI: 10.11613/BM.2021.010502

22. Shastri A., Al Aiyan A., Kishore U. et al. Immune-mediated neuropathies: Pathophysiology and management. Int J Mol Sci 2023;14;24(8):7288. DOI: 10.3390/ijms24087288

23. Doneddu P.E., Dentoni M., Nobile-Orazio E. Atypical chronic inflammatory demyelinating polyradiculoneuropathy: Recent advances on classification, diagnosis, and pathogenesis. Curr Opin Neurol 2021;1;34(5):613–24. DOI: 10.1097/WCO.0000000000000979

24. Draak T.H., Vanhoutte E.K., van Nes S.I. et al. Comparing the NIS vs. MRC and INCAT sensory scale through Rasch analyses. J Peripher Nerv Syst 2015;20(3):277–88. DOI: 10.1111/jns.12127